Evidence map›Paper›PMID 36264955›Full record

SynthesisPloS one2022

Bicarbonate defective CFTR variants increase risk for chronic pancreatitis: A meta-analysis.

Gergő Berke, Noémi Gede, Letícia Szadai, Klementina Ocskay, Péter Hegyi, Miklós Sahin-Tóth, Eszter Hegyi

Open access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Pancreatic Hyperenzymemia in Inflammatory Bowel Disease: Clinical Characterization and Outcomes from the European PANDORA Registry.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026
    Article
  3. Article
  4. Frontiers in endocrinology · 2026
    Review
  5. Review
  6. Review
  7. Review
  8. A De NovoBiomedicines · 2024
    Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Gergő BerkeInstitute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
Noémi GedeInstitute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
Letícia SzadaiDepartment of Dermatology and Allergology, University of Szeged, Szeged, Hungary.ORCID 0000-0002-3605-839X
Klementina OcskayInstitute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
Péter HegyiInstitute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
Miklós Sahin-TóthDepartment of Surgery, University of California, Los Angeles, Los Angeles, California, United States of America.ORCID 0000-0003-4513-9922
Eszter HegyiInstitute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.ORCID 0000-0002-9137-7561
University of Pecs · HUSemmelweis University · HUUniversity of California, Los Angeles · USUniversity of Szeged · HU

Funding

Chymotrypsin in pancreatitisR01DK082412 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SAHIN-TOTH, MIKLOS · 2009 to 2024
$5.8M
Trypsin-dependent mechanisms in pancreatitisR01DK117809 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SAHIN-TOTH, MIKLOS · 2018 to 2022
$2.5M
NIDDK NIH HHS R01 DK082412NIDDK NIH HHS R01 DK117809
6 · The paper itself

Abstract

introductionCystic fibrosis transmembrane conductance regulator (CFTR) plays a central role in pancreatic ductal fluid secretion by mediating Cl- and HCO3- ion transport across the apical membrane. Severe CFTR mutations that diminish chloride conductance cause cystic fibrosis (CF) if both alleles are affected, whereas heterozygous carrier status increases risk for chronic pancreatitis (CP). It has been proposed that a subset of CFTR variants characterized by a selective bicarbonate conductance defect (CFTRBD) may be associated with CP but not CF. However, a rigorous genetic analysis of the presumed association has been lacking.

aimsTo investigate the role of heterozygous CFTRBD variants in CP by meta-analysis of published case-control studies. MATERIALS AND

methodsA systematic search was conducted in the MEDLINE, Embase, Scopus, and CENTRAL databases for published studies that reported the CFTRBD variants p.R74Q, p.R75Q, p.R117H, p.R170H, p.L967S, p.L997F, p.D1152H, p.S1235R, and p.D1270N in CP patients and controls.

resultsTwenty-two studies were eligible for quantitative synthesis. Combined analysis of the 9 CFTRBD variants indicated enrichment in CP patients versus controls (OR = 2.31, 95% CI = 1.17-4.56). Individual analysis of CFTRBD variants revealed no association of p.R75Q with CP (OR = 1.12, 95% CI = 0.89-1.40), whereas variants p.R117H and p.L967S were significantly overrepresented in cases relative to controls (OR = 3.16, 95% CI = 1.94-5.14, and OR = 3.88, 95% CI = 1.32-11.47, respectively). The remaining 6 low-frequency variants gave inconclusive results when analyzed individually, however, their pooled analysis indicated association with CP (OR = 2.08, 95% CI = 1.38-3.13).

conclusionHeterozygous CFTRBD variants, with the exception of p.R75Q, increase CP risk about 2-4-fold.

Indexed as

Cystic Fibrosis Transmembrane Conductance RegulatorPancreatitis, ChronicBicarbonatesChloridesCystic FibrosisHumansMutationBicarbonatesCFTR protein, humanChloridesCystic Fibrosis Transmembrane Conductance Regulator

Identifiers

PMID36264955
PMCPMC9584382
OpenAlexW4306896975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.